Navigation Links
Preventing toxic shock syndrome and other severe diseases

A researcher at The University of Western Ontario has received over $603,000 from the Canadian Institutes of Health Research (CIHR) to investigate how and why a group of bacterial toxins leads to the development of toxic shock syndrome and other serious diseases. John McCormick is an associate professor in the Department of Microbiology and Immunology at the Schulich School of Medicine & Dentistry, and a scientist with the Lawson Health Research Institute. His research is one of 18 projects at Western and Lawson to receive new CIHR operating grants totaling more than $9.55 million.

"We are looking at how these superantigen toxins bind to proteins on the surface of white blood cells. This binding causes the over-activation of the immune system which can result in the patient developing shock," says McCormick. The bacteria that produce these toxins include Streptococcus pyogenes (responsible for flesh-eating disease) and Staphylococcus aureus, including methicillin-resistant S. aureus, also known as the "MRSA" superbug.

"A patient can have a localized infection, for example, a staph infection in their toe, and that bacteria will release toxins which will go systemic, all through the body, even though the infection hasn't spread. The infection can be treated with antibiotics, but that won't have any affect on the toxins," explains McCormick. "By understanding how these toxins work, we can look at developing drug inhibitors that will target and neutralize the toxins."

On the flip side, McCormick believes these toxins could be utilized to fight cancer. "We know these toxins cause potent activation of the immune system, so if we could engineer them to bind only to cancer cells, we could get the immune system to destroy the cancer. That's a long-term goal we have."


Contact: Kathy Wallis
519-661-2111 x81136
University of Western Ontario

Page: 1

Related medicine news :

1. Blood-flow detector software show promise in preventing brain damage
2. Preventing variceal bleeding
3. OSHA Issues Draft Ergonomics Guidelines on Preventing Musculoskeletal Injuries in Shipyards
4. Preventing or reducing enlarged heart decreases risk of heart failure
5. Pill Equals Injection in Preventing Clots After Hip Replacement
6. Treating obstructive sleep apnea, preventing heart attacks and strokes
7. Preventing lung scarring may extend lives of lung cancer patients
8. Preventing or reducing enlarged heart may decrease risk for diabetes
9. Study shows drug effective in treating, preventing breast cancer
10. Good Hygiene Is Key to Preventing MRSA
11. Preventing Cancer, This Week on Your Cancer Today(TM)
Post Your Comments:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: